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Thenucleus pulposus (NP) of intervertebral discs experiences
dynamic changes in tissue osmolarity because of diurnal loading
of the spine. TonEBP/NFAT5 is a transcription factor that is
critical in osmoregulation as well as survival of NP cells in the
hyperosmotic milieu. The goal of this study was to investigate
whether cyclooxygenase-2 (COX-2) expression is osmorespon-
sive and dependent on TonEBP, and whether it serves an osmo-
protective role. NP cells up-regulated COX-2 expression in
hyperosmoticmedia. The induction of COX-2 depended on ele-
vation of intracellular calcium levels and p38 MAPK pathway,
but independent of calcineurin signaling as well as MEK/ERK
and JNK pathways. Under hyperosmotic conditions, both
COX-2mRNA stability and its proximal promoter activity were
increased. The proximal COX-2 promoter (1840/123 bp)
contained predicted binding sites for TonEBP, AP-1, NF-B,
and C/EBP-. While COX-2 promoter activity was positively
regulated by both AP-1 and NF-B, AP-1 had no effect and
NF-B negatively regulated COX-2 protein levels under hyper-
osmotic conditions.Ontheotherhand,TonEBPwasnecessary for
both COX-2 promoter activity and protein up-regulation in
response to hyperosmotic stimuli. Ex vivo disc organ culture stud-
ies using hypomorphic TonEBP/mice confirmed that TonEBP
is required forhyperosmotic inductionofCOX-2. Importantly, the
inhibition of COX-2 activity under hyperosmotic conditions
resulted in decreased cell viability, suggesting that COX-2 plays a
cytoprotectiveandhomeostaticrole inNPcells for theiradaptation
to dynamically loaded hyperosmotic niches.
The nucleus pulposus (NP)3 has a complex matrix that
consists of primarily large aggregating proteoglycan aggre-
can within the network of collagen II. High concentration of
negatively charged sulfated glycosaminoglycans on aggrecan
allows the NP to attract sodium ions within the tissue, resulting
in physiologically elevated osmolarity compared with sur-
rounding tissues. These cations also cause the NP tissue to
imbibewater, providing high osmotic swelling pressure respon-
sible for the ability of discs to resist compressive loads in the
spine (1, 2). The increased matrix degradation by proteolysis,
changes in matrix composition, and inflammatory signaling
result in compromised mechanical function as well as
decreased osmolarity during intervertebral disc degeneration
(3–6). Moreover, the efflux and influx of water from discs
caused by diurnal loading of the spine lead to dynamic changes
of osmolarity in NP tissue. As a result, NP cells have evolved to
adapt to the changes in extracellular osmolarity.
Tonicity-responsive enhancer-binding protein (TonEBP/
nuclear factor of activated T-cells 5 (NFAT5)) is a Rel homo-
logy transcription factor, whose induction is coupled to
hyperosmolarity. TonEBP promotes cell survival by regulat-
ing the expression of osmoprotective genes in a variety of
tissues including NP (7, 8). Under osmotic stress, TonEBP
prevents excess influx of sodium by controlling the intracel-
lular levels of nonionic osmolites such as taurine, sodium/
myoinositol, and betaine through regulation of their trans-
porters and enzymes involved in their synthesis: taurine
transporter (TauT), betaine-GABA transporter (BGT-1),
sodium/myoinositol cotransporter (SMIT), and aldose re-
ductase (AR) (8–12). Additionally, heat shock protein 70
(HSP 70), a chaperone involved in cellular trafficking, protein
folding, and degradation of misfolded proteins, is regulated by
TonEBP under hyperosmotic condition (13).
In Madin-Darby canine kidney cells, TonEBP has been
shown to regulate cyclooxygenase-2 (COX-2), an enzyme nec-
essary for prostaglandin (PG) synthesis (14). PGs are important
for regulating renal salt and water balance as well as inflamma-
tion (15). Other members of the NFAT family also control
COX-2 expression under various stimuli, including hyperos-
molarity (16–18).Whereas in renal cells COX-2 is linked to cell
survival and osmo-adaptation (19–21), its regulation and func-
tion in the setting of hyperosmolarity remain largely unex-
plored in the disc. The objective of this study was to elucidate
how COX-2 expression is controlled in the hyperosmotic
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milieu of NP cells as well as its functional implications. We
show that COX-2 expression is up-regulated under hyperos-
motic conditions through intracellular calcium independent of
calcineurin signaling. In addition,we determine that this induc-
tion is through TonEBP-mediated increase in COX-2 proximal
promoter activity and its mRNA stability. Importantly, our
study demonstrates that COX-2 plays cytoprotective and
osmo-adaptive role in the hyperosmotic microenvironment of
the intervertebral disc.
Results
Hyperosmolarity and increased intracellular calcium
up-regulate COX-2 expression in NP cells
The effect of hyperosmolarity on COX-2 expression was
examined by culturingNP cells under hyperosmotic conditions
and measuring COX-2 mRNA and protein levels. COX-2
mRNA levels were significantly increased in response to NaCl
treatment at 4 h, and decreased to below the baseline level by
24 h (Fig. 1A). Treating NP cells with NaCl up to 170 mM
resulted in COX-2 mRNA up-regulation (Fig. 1B). All the
remaining experiments in this study were done with 110 mM
NaCl. Because extracellular hyperosmolarity leads to increased
[Ca2]i in NP cells (22, 23), we examined the effect of increased
[Ca2]i on COX-2 levels. Treatment with calcium ionophore,
ionomycin, with phorbol 12-myristate 13-acetate (PMA)
resulted in a significant induction of COX-2mRNA at 4 and 8 h
(Fig. 1C). Although there was a decrease in the levels of COX-2
at 24 h post ionomycin/PMA treatment, the levels remained
higher than the baseline (Fig. 1C). Western blot analyses dem-
onstrated induction of COX-2 protein levels in response to
hyperosmolarity and ionomycin/PMA treatment (Fig. 1,D–G).
COX-2 protein levels were significantly up-regulated at 4 and
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Figure 1. COX-2 is up-regulated in response to hyperosmolarity and high intracellular calcium in NP cells. A and B, qRT-PCR analysis demonstrates (A)
time- and (B) dose-dependent COX-2 mRNA increase under hyperosmotic conditions. C, COX-2 mRNA is induced by ionomycin/PMA (I P) treatment. D and
E, Western blots of COX-2 after NaCl or IP time course treatments show significant induction of COX-2 expression. F andG, densitometry analyses ofWestern
blots fromD and E.H, immunofluorescence staining of COX-2 in NP cells confirms that its expression is increasedwithNaCl aswell as I P treatment. Scale bar:
50 m. All the quantitative data are represented as mean S.D. from at least three independent experiments. *, p 0.05.
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8 h post hyperosmolarity and ionomycin treatments. Immuno-
fluorescence staining supported theWestern blot data showing
increased COX-2 levels with NaCl or ionomycin/PMA treat-
ment (Fig. 1H).
Induction of COX-2 is independent of calcineurin pathway
Because calcineurin is an important mediator of calcium sig-
naling, we investigated whether hyperosmolarity-induced
COX-2 up-regulation in NP cells involved calcineurin path-
way. Cells were treated with NaCl with or without BAPTA, a
potent calcium chelator, or FK-506 and cyclosporin A (CsA),
calcineurin inhibitors. Reducing intracellular calcium levels
using BAPTA inhibited hyperosmotic induction of COX-2
mRNA and protein (Fig. 2, A–C). However, FK-506/CsA
treatment did not alter the NaCl-induced COX-2 levels,
indicating that COX-2 induction was independent of cal-
cineurin signaling (Fig. 2, A–C). Similarly, ionomycin/PMA-
dependent induction of COX-2 mRNA and protein levels
were completely abolished by BAPTA, but not by FK-506/
CsA, confirming that calcineurin did not play a role in this
process (Fig. 2, D–F).
p38MAPK pathwaymediates hyperosmotic induction of
COX-2
Hyperosmolarity as well as calcium signaling is known to
activate MAPK signaling pathways (24–28). Previous studies
also showed that MAPK pathways regulate COX-2 expression
in some cell types (29, 30). We therefore investigated if this
pathway contributed to regulation of COX-2 expression in NP
cells. We first determined the changes in activation status of
p38 in NP cells under hyperosmotic condition. Phospho-p38
levels were rapidly increased as early as 15 min and stayed sig-
nificantly up-regulated until 1 h following NaCl treatment (Fig.
3, A and B). Although there was a trend of increasing phospho-
p38 at 5 min, 4 h, and 24 h, it did not reach statistical signifi-
cance. We then treated NP cells with MAPK inhibitors includ-
ing SB202190, p38 inhibitor; PD98059, MEK/ERK inhibitor;
and SP600125, JNK inhibitor, under hyperosmotic conditions
andmeasuredCOX-2 levels. TreatingNPcellswithp38 inhibitor
resulted in blockage of hyperosmotic induction of COX-2mRNA
(Fig. 3C). However, inhibition of MEK/ERK or JNK pathways did
not affect COX-2 induction (Fig. 3D). Similarly, COX-2 protein
up-regulation in response to NaCl treatment was abolished with
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Figure2.Hyperosmolarity-mediated inductionofCOX-2 is through intracellular calciumbut independentof calcineurin signaling.A–C, hyperosmotic
induction of COX-2 mRNA (A), and protein (B and C) is suppressed by BAPTA, a calcium chelator, but is unaffected by FK-506/CsA (F/C), a calcineurin inhibitor.
D–F, induction of COX-2 mRNA (D) and protein (E and F) in response to ionomycin/PMA (I P) treatment is completely abolished with BAPTA, but not with
FK/CsA treatment. All the quantitative data are represented as mean  S.D. from at least three independent experiments (three biological replicates). NS:
nonsignificant; *, p 0.05.
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p38 inhibition, indicating that p38MAPK is involved in hyperos-
motic induction of COX-2. However, when NP cells were treated
with ionomycin/PMA, p38 inhibition hadno effect onCOX-2up-
regulation (Fig. 3,E–G), suggesting that p38MAPK is dispensable
to ionomycin-induced COX-2 expression.
Hyperosmolarity increases COX-2 transcription as well as its
mRNA stability
To further elucidate the mechanism of COX-2 induction by
hyperosmolarity, we first investigated if hyperosmolarity affects
COX-2 mRNA stability. Actinomycin D chase study showed that
in NP cells, the half-life of COX-2 mRNA under isoosmotic con-
dition was 2 h, whereas under hyperosmotic condition it was
longer than6h (Fig. 4A), suggesting that increasedCOX-2 expres-
sion was in part due to elevatedmRNA stability.
Because MAPK pathways are involved in activation of vari-
ous transcription factors, we investigated if hyperosmotic
induction of COX-2was also transcriptionally regulated. Lucif-
erase reporter assays were performed using COX-2 promoter
fragment (1840/123 bp) that has shown transcriptional reg-
ulatory activity in other cell types (31). Genomatix MatInspec-
tor software was used to scan potential TonE- and other rele-
vant transcription factor–binding sites within the COX-2
promoter (Fig. 4B). Putative binding sites and consensus
sequence for each transcription factorwith four core consensus
bp in capital letters are listed in the table (Fig. 4C). Matrix sim-
ilarity score based on the most conserved nucleotide at each
position of the matrix is also shown. Four TonE sites as well as
binding sites for AP-1, C/EBP-, and NF-B were identified.
We assessed the sensitivity of the promoter to hyperosmotic
stimuli; the promoter activity was significantly increased at 4 h,
and then declined at 24 h (Fig. 4D). COX-2 promoter activity
also showed dose-dependent induction in response to hyperos-
molarity (Fig. 4E). In addition, hyperosmotic induction of
COX-2 promoter activity was reduced to basal level when the
cells were treated with BAPTA, supporting our earlier data on
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Figure 3. Hyperosmotic induction of COX-2 is mediated by p38, but not by ERK or JNK. A and B, phospho-p38 (p-p38) levels significantly increase in
response to hyperosmolarity. C and D, hyperosmotic increase of COX-2 mRNA is completely suppressed by p38 inhibitor, SB202190, but unaffected by JNK
inhibitor, SP600125, and MEK/ERK inhibitor, PD98059. E, Western blot images showing that p38 inhibition prevents COX-2 induction in response to hyperos-
molarity. F, Western blot images showing that ionomycin/PMA (I P)-mediated COX-2 induction is not affected by p38 inhibition.G, densitometry analyses of
Western blots shown in E and F. All the quantitative data are represented as mean  S.D. from at least three independent experiments (three biological
replicates). NS: nonsignificant; *, p 0.05. PD: PD98059 (MEK/ERK inhibitor); SB90: SB202190 (p38 inhibitor); SP: SP600125 (JNK inhibitor).
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calcium-dependent induction of COX-2 mRNA and protein
levels under hyperosmotic conditions (Fig. 4F). Similarly, when
the cells were treated with p38 inhibitor under hyperosmotic
condition, COX-2 promoter activity was decreased to that of
baseline (Fig. 4G). Interestingly, inhibition of p38 under isoos-
motic condition resulted in increasedCOX-2 promoter activity
(Fig. 4G). Furthermore, althoughCOX-2mRNA levelswere not
affected, its promoter activity was significantly reduced by
MEK/ERK inhibitor (Fig. 4H). These results indicated that
hyperosmotic induction of COX-2 was because of increased
mRNA stability as well as transcription.
AP-1, C/EBP-, and NF-B do not contribute to hyperosmotic
induction of COX-2 expression
Because we identified several potential transcription factor–
binding sites in the 1.8 kb proximal promoter region of
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COX-2, we determined whether these transcription factors
were responsible for modulating COX-2 transcription. AP-1
has been shown to regulate COX-2 expression (32, 33), and we
and others have shown that AP-1 and TonEBP coregulate
expression of certain target genes (28, 34). Therefore, we first
investigated if AP-1 activity was modified under hyperosmotic
conditions. AP-1–responsive reporter activity showed signifi-
cant increase in response to NaCl treatment (Fig. 5A). In addi-
tion, dominant negative (DN)–AP-1 (A-Fos) significantly sup-
pressed COX-2 promoter activity under both isoosmotic and
hyperosmotic conditions (Fig. 5B). Surprisingly however,
COX-2 protein levels remained elevated when NP cells were
treated with AP-1–specific inhibitor, SR11302, under hyperos-
motic condition (Fig. 5, C and D). Inhibition of AP-1 under
isoosmotic condition also resulted in elevated COX-2 levels,
suggesting that AP-1 is a negative regulator of COX-2 in NP
cells.
NF-B has also been shown to control COX-2 expression
in other types of cells under hyperosmotic conditions (35,
36). For example, renal medullary interstitial cells up-regu-
late COX-2 in response to hyperosmotic stimuli through co-
activation of NF-B and C/EBP- (36). We investigated
whether such regulatory mechanism exists in NP cells.
Transfecting cells with DN–NF-B resulted in slight but
statistically significant decrease in COX-2 promoter acti-
vity under both isoosmotic and hyperosmotic conditions,
whereas DN–C/EBP- did not affect COX-2 promoter activ-
ity (Fig. 5E). However, in contrast to the decreased promoter
activity, COX-2 mRNA as well as protein levels were further
up-regulated by NF-B inhibitor, SM7368 (Fig. 5, F, G, and
I), suggesting that NF-B was not responsible for hyperos-
motic induction of COX-2 but rather served as a negative
regulator in NP cells. Interestingly, when cells were treated
with ionomycin/PMA, NF-B inhibition had no significant
effect on COX-2 expression (Fig. 5, H and I), suggesting
that NF-B is not involved in ionomycin-induced COX-2
expression.
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TonEBP regulates COX-2 expression in response to
hyperosmolarity
Because TonEBP/NFAT5 is an important mediator of
osmotic response and known to be activated in a calcium-de-
pendent but calcineurin-independent manner (22, 23), and
because COX-2 proximal promoter had four predicted
TonEBP-binding sites, we investigated whether hyperosmotic
induction of COX-2 inNP cells was throughTonEBP. To assess
the role of TonEBP in regulation of COX-2 promoter, we
performed gain- and loss-of-function experiments. TonEBP
overexpression increased, whereas DN–TonEBP significantly
decreased COX-2 promoter activity (Fig. 6, A and B). The
involvement ofTonEBP inCOX-2 regulationwas further tested
through stably silencing TonEBP by transducing NP cells
with lentivirus expressing either control or TonEBP-targeting
shRNA. In the absence ofTonEBP, hyperosmotic up-regulation
of COX-2 mRNA was inhibited (Fig. 6C). Under both isoos-
motic and hyperosmotic conditions, COX-2 protein levels
were significantly decreased by TonEBP silencing (Fig. 6,D and
E), indicating that hyperosmotic induction of COX-2 was
TonEBP-dependent. To confirm these findings, we analyzed
COX-2 expression in WT and TonEBP null mouse embryonic
fibroblasts (MEFs) in response to hyperosmolarity and ionomy-
cin/PMA treatments. Under both conditions, WT MEFs in-
creased COX-2 expression. In contrast, TonEBP null MEFs
failed to up-regulate COX-2 levels (Fig. 7, A and B). We also
performed an ex vivo organ culture study using intervertebral
discs from WT (TonEBP/) and haploinsufficient TonEBP
heterozygous mice (TonEBP/) (Fig. 7C). Culturing under
hyperosmotic condition resulted in COX-2 mRNA up-regula-
tion in theWT discs, but not in the TonEBP/ discs (Fig. 7D),
further supporting the role of TonEBP in regulating COX-2
expression under hyperosmotic condition.
COX-2 activity promotes NP cell survival
Because many of the TonEBP targets induced under osmotic
stress promote cell survival, we investigated the functional
importance of COX-2 under hyperosmotic condition. NP cell
viability was measured following culture in isoosmotic or
hyperosmotic media, with or without celecoxib, a COX-2
inhibitor. Celecoxib treatment reduced cell viability under
isoosmotic condition (Fig. 7E). Moreover, under hyperosmotic
condition, celecoxib treatment resulted in even further cell death,
suggesting thatCOX-2playsan importantcytoprotective function
in NP cells (Fig. 7E). To further delineate if COX-2–mediated cell
survival was through inhibition of caspase activity, we treated cells
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with different caspase inhibitors in the presence of celecoxib.
Interestingly, treatment with AZ10417808 (caspase-3 inhibitor),
Z-IE(OMe)TD(OMe)–FMK (caspase-8 inhibitor), or Boc-D-
FMK (pan caspase inhibitor) failed to block cell death caused by
celecoxib (Fig. 7E), suggesting that COX-2 did not mediate its
cytoprotective effects through inhibition of caspase activity.
Discussion
In this study, we elucidated the mechanism of COX-2
expression in NP cells in response to hyperosmotic stress. We
demonstrated that COX-2 mRNA and protein were up-regu-
lated by hyperosmolarity through calcium signaling activating
p38 and TonEBP. Our data suggested that both COX-2 tran-
scription and COX-2 mRNA stability were increased under
hyperosmotic condition. Interestingly, both processes were de-
pendent on TonEBP as shown by gain- and loss-of-function
studies andTonEBP/mouse disc ex vivo organ culture study.
The functional analysis showed that COX-2 activity was crucial
for NP cell survival not only under isoosmotic condition, but
more so under hyperosmotic stress. Taken together, our study
showed that COX-2 is a TonEBP target in NP cells, and that it
plays a cytoprotective role during acute osmotic challenge.
Several studies have shown that different stimuli, including
high glucose levels, dehydration-caused hyperosmolarity, and
inflammatory stimuli, can induceCOX-2 expression (14, 16, 17,
35, 37). Our results showed that COX-2was induced inNP cells
D
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in response to osmotic challenge as well as ionomycin/PMA
treatment. Both stimuli resulted in the highest induction of
COX-2 by 4 h and significant decrease at 24 h following hyper-
osmotic stimulus. This suggested that COX-2 induction is a
relatively early response and that the temporal regulation of its
expression is important. In various cell types, COX-2 expres-
sion is regulated by intracellular calcium through several path-
ways including calcineurin-NFAT as well as reactive oxygen
species (ROS) and cAMP activation (18, 39–41). The data from
our studies using calcium chelator BAPTA confirmed that
hyperosmolarity- and ionomycin-mediated COX-2 expression
is through changes in intracellular calcium levels. Interestingly,
whenNP cells were treated with calcineurin inhibitors FK-506/
CsA, COX-2 induction by hyperosmolarity or ionomycin
remained unaltered, indicating that COX-2 up-regulation in
response to hyperosmolarity or ionomycin is independent of
calcineurin-NFAT pathway.
In renal medullary interstitial cells, MAPK pathway, known
to be downstream of calcium signaling, modulates COX-2
expression under hyperosmotic condition (29, 30). Our data
clearly showed that MAPK, specifically p38, was involved in
hyperosmotic induction of COX-2 in NP cells. On the other
hand, COX-2 induction by ionomycin treatment was not
responsive to p38 inhibition, indicating that in presence of
excessively high levels of intracellular calcium, p38 activity is
redundant in promoting COX-2.
MAPK pathways have been shown to regulate multiple tran-
scription factors, includingTonEBP,NFATs, AP-1, andNF-B,
that have been implicated in COX-2 regulation (14, 16, 17, 32,
33, 35, 36).Our analysis showed thatCOX-2 promoter hasmul-
tiple predicted binding sites for TonEBP as well as other tran-
scription factors. Induction of COX-2 promoter activity under
hyperosmotic condition that mirrors the mRNA expression
profile showed that the increase in COX-2 expression was in
part because of increased transcription.Moreover, COX-2 pro-
moter sensitivity to BAPTA treatment confirmed that this tran-
scriptional induction was calcium-dependent. Importantly,
actinomycin D chase experiment clearly demonstrated that
COX-2mRNAwas significantly stabilized under hyperosmotic
condition, indicating that up-regulation of COX-2 is because of
combinatorial effect of transcriptional regulation and increased
mRNA stability.
Both AP-1 and NF-B have been implicated in COX-2 regu-
lation in a cell type– and context-dependent manner (35, 36).
Our promoter studies revealed that although both transcrip-
tion factors modulated COX-2 promoter activity, under hyper-
osmotic conditions, AP-1 did not regulate COX-2 protein
levels, whereas, NF-B evidenced a negative relationship to
COX-2 levels. This discordance suggests that AP-1 and NF-B
do not control COX-2 transcription through its proximal pro-
moter in response to hyperosmotic stimuli, and that they are
not the primary inducers of hyperosmolarity-mediated COX-2
expression in NP cells. In addition, despite the presence of
C/EBP-–binding sites, these sites did not contribute to hyper-
osmotic regulation of COX-2 promoter activity.
Our earlierwork has shown that hyperosmolarity-dependent
TonEBP activation in NP cells was through increased [Ca2]i,
yet did not involve calcineurin pathway (22, 23). Likewise, both
PKA and ROS have been linked to TonEBP activation (43, 44).
We therefore hypothesized that TonEBP may be involved in
COX-2 regulation. There have been a few studies demonstrat-
ing association between TonEBP and COX-2 expression in dif-
ferent cell types (14, 45). However, none of the previous studies
have investigated the role of TonEBP in controlling COX-2
proximal promoter activity. Our analysis predicted four TonE
sites within the proximal 1.8 kb promoter region of COX-2.
TonEBP gain- and loss-of-function experiments showed that
COX-2 promoter activity was responsive to TonEBP. In con-
trast to AP-1 andNF-B, stable silencing of TonEBP resulted in
inhibition of hyperosmotic up-regulation of COX-2 inNP cells.
Further support for TonEBP contribution to COX-2 regulation
was evident from analyses of TonEBP null MEFs. COX-2 pro-
tein expression was responsive to neither hyperosmolarity nor
high intracellular calcium in TonEBP null MEFs. Importantly,
ex vivo disc organ culture studies using haploinsufficient
TonEBP/mice firmly supported in vitro studies. In the inter-
vertebral discs of TonEBP/ mice, COX-2 gene expression
was not induced by hyperosmolarity, confirming that TonEBP
is necessary for COX-2 expression under hyperosmotic stress
in NP cells. Although TonEBP has been associated with both
AP-1 and NF-B in regulating certain targets in NP cells under
certain conditions (28, 45–47), this was not the case in control-
lingCOX-2 expression, implying its target-specificity. Further-
more, complete inhibition of COX-2 up-regulation in the
absence of TonEBP indicated that TonEBP not only tran-
scriptionally regulates COX-2, but also indirectly stabilizes
COX-2 mRNA under hyperosmotic condition. Interestingly,
the magnitude of increase in COX-2 promoter activity in
response to hyperosmolarity or TonEBP overexpression is
subdued compared with the increase in half-life of COX-2
mRNA. This suggests that, unlike in other cell types, the
main mode of TonEBP regulation of COX-2 in NP may be
through mRNA stabilization.
The function of COX-2 as an osmoprotective factor has been
shown in leukemia (48) and renal cells (19–21). NP cells, simi-
lar to renal cells, require tight osmoregulation to protect cells
from deleterious effects of dynamic changes in osmolarity and
mechanical loading. Therefore, we hypothesized that TonEBP-
mediated dynamic COX-2 expression serves a cytoprotective
and homeostatic role rather than an inflammatory function in
NP cells. Cell viability assay followingCOX-2 activity inhibition
clearly demonstrated that COX-2 activity contributed to NP
cell survival regardless of extracellular osmolarity. It is note-
worthy that inhibition of caspases did not rescue compromised
cell viability caused by COX-2 inhibition, indicating that the
observed cell death was caspase-independent. This was differ-
ent from what has been seen in leukemia cells, where COX-2
promotes cell survival by activating anti-apoptotic proteins
Bcl-2 and Bcl-xL, and preventing caspase-3, poly [ADP-ribose]
polymerase (PARP), and lamin B cleavage through its target,
PGE2 (48).
Taken together, our study demonstrated that calcium-
MAPK-TonEBP axis plays a critical role in controlling COX-2
expression in NP cells under hyperosmotic condition, and that
COX-2 serves a prosurvival function. It should be noted that
the function of COX-2 is context-dependent as has been dem-
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onstrated in the cases of fracture healing and inflammatory dis-
eases of bone and other tissues (49–51). Inhibition of COX-2
has been shown to be beneficial in treating inflammation of
herniated discs as well (52). Our study reveals a novel function
of COX-2 in maintaining intervertebral disc health, and has an
important clinical implication as chronic use of NSAIDs for
back pain or other musculoskeletal diseases may alleviate pain
and reduce inflammation in pathological discs but can also
inhibit COX-2 in other healthy discs, adversely affecting theNP
health. Therefore, it is crucial to understand underlying mech-
anisms that distinguish physiological and homeostatic versus
pathological roles of COX-2 in the disc. Our study provides a
better understanding on the regulatory mechanism of a key
cellular pathway necessary for NP cell survival and function.
Experimental procedures
Reagents and plasmids
Plasmids were kindly provided by Drs. Ben C. Ko, University
of Hong Kong (FLAG–DN–TonEBP, FLAG–TonEBP, FLAG–
CMV2 (53); DN–TonEBP contains amino acids 157 through
581 of human TonEBP (from clone KIAA0827)); Charles Vin-
son, NIH (DN–AP-1); Silvio Gutkind, NIH (AP-1 reporter);
DanDixon, University of SouthCarolina (1.8 kb humanCOX-2
promoter luciferase reporter construct (31)). psPAX2 (no.
12260) and pMD2.G (no. 12259) developed by Dr. Didier
Trono, and pCMV–FLAG–LIP (DN–C/EBP-; no. 15737) by
Dr. Joan Massague were obtained from Addgene. Lentiviral
shTonEBP (TRCN0000020019) and control shRNA plasmids
were purchased from Sigma. TonEBP/NFAT5 WT and null
MEFs (from Dr. Steffan N. Ho) (42) were provided by Dr. Feng
Chen, Washington University, St. Louis. TonEBP/ and hap-
loinsufficient TonEBP/ developed by Dr. Steffan Ho (42)
were a kind gift fromH.MooKwon, UlsanNational Institute of
Science and Technology.
Cell culture and treatments
Rat NP cells were isolated using a method previously
reported by Risbud et al. (38) and approved by Jefferson’s Insti-
tutional Animal Care and Use Committee. Cells were main-
tained in DMEM with 10% FBS supplemented with antibiotics
until confluent. For hyperosmolarity treatment, 110 or 170 mM
NaCl was added to the culture media for NP cells, resulting in
550 and 670 mOsM kg1 media, respectively, and 85 mM NaCl
was added to the culturemedia for TonEBPWTand nullMEFs,
resulting in 500 mOsM kg1 media. In some experiments, cells
were treatedwith 1M ionomycin (Sigma) and 100 ng/ml PMA
(Sigma) with or without pretreatment with either 10 M
BAPTA/AM (EMD Millipore) or FK-506 (10 ng/ml)/CsA (1
g/ml) (EMD Millipore) for 1.5 h. In some experiments, cells
were pretreated with 10 M SB202190 (Tocris Bioscience), 10
MPD98059 (Tocris), 10MSP600125 (Sigma), 10MSM7368
(Calbiochem), 10 M SR11302 (Tocris), 30 M AZ10417808
(Tocris), 20 M Z-IE(OMe)TD(OMe)-FMK (Calbiochem), 100
M Boc-D-FMK (Calbiochem), or 40 M celecoxib (Sigma) for
1–1.5 h prior to NaCl or iononomycin/PMA treatment.
Real-time RT-PCR analysis
Total RNA was extracted from NP cells using RNeasy Mini
columns (Qiagen). The purified, DNA-free RNAwas converted
to cDNA using RNA to cDNA EcoDryTM Premix (Clontech).
Template cDNA and gene-specific primers were added to
SYBR Green Master Mix (Applied Biosystems) and mRNA
expression was quantified using the Step One Plus Real-Time
PCR System (Applied Biosystems).-actin was used to normal-
ize gene expression. All the primers used were synthesized by
Integrated DNA Technologies, Inc. (Coralville, IA).
Bioinformatic analysis of promoter
Human COX-2 proximal promoter sequence was down-
loaded from the University of California, Santa Cruz Genome
Table Browser.MatInspector (Genomatix) was used to identify
predicted binding sites for TonEBP as well as AP-1, NF-B, and
C/EBP- with a Matrix Similarity Score cutoff of 0.8.
Transfections and dual luciferase assay
Cells were plated on 48-well plates (2 104 cells/well) 1 day
before transfection. Cells were transfected with 250 ng of
COX-2 reporter plasmid and 250 ng of pRL-TK plasmid, or 150
ng of COX-2 reporter plasmid, 150 ng of various dominant-
negative or overexpression plasmids, with or without appropri-
ate backbone vector, and 200 ng of pRL-TK plasmid. For each
transfection, plasmids were premixed with the transfection re-
agent Lipofectamine 2000 (Invitrogen). The treatments were
done so that the cells were lysed 48 h after the transfection.
Dual-LuciferaseTM reporter assay system (Promega) was used
for sequential measurements of firefly and Renilla luciferase
activities using TECAN Infinite200 Pro microplate reader
(TECAN). At least three independent transfections were per-
formed and all analyses were carried out in triplicate.
Protein extraction andWestern blotting
Following treatment, cells were immediately placed on ice
andwashedwith ice-cold PBS. All thewash buffers and the final
cell lysis/resuspension buffers included 1 protease inhibitor
mixture (Roche), NaF (5 mM), and Na3VO4 (200 M). Proteins
were resolved on 10% SDS-polyacrylamide gels and transferred
by electroblotting to PVDF membranes (Bio-Rad). The mem-
branes were blocked with 5% nonfat dry milk in TBS with
Tween 20 and incubated overnight at 4 °C in 5%nonfat drymilk
in TBS with Tween 20 with the antibodies against COX-2
(1:1000; no. 12282, rabbit, Cell Signaling Technology), phos-
pho-p38 (1:1000; no. 8690, rabbit, Cell Signaling Technology),
NFAT5 (1:1000; no. NB120–3446, rabbit, Novus), or GAPDH
(1:3000; NB300–221, mouse, Novus), and then appropriate
secondary antibodies for 1 h at room temperature. Immuno-
labeling was detected using the ECL reagent (Amersham
Biosciences).
Immunofluorescencemicroscopy
NP cells were plated on glass coverslips. Following treatment
cells were fixed and permeabilized with cold methanol at
20 °C for 15 min, blocked with 5% normal goat serum in PBS
with 0.3%Triton X-100 for 1 h at room temperature. Cells were
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incubated with anti–COX-2 antibody (1:800; no. 12282, rabbit,
Cell Signaling Technology) at 4 °C overnight, then incubated
with Alexa Fluor 594 secondary antibody (1:800; Jackson
ImmunoResearch Laboratories) at room temperature for 1 h.
Cells were washed and were mounted with ProLongTM Gold
Antifade Mountant with DAPI (Thermo Fisher). All mounted
slides were visualized using a Zeiss Axio ImagerA2 (Carl Zeiss).
Cell viability assay
To measure cell viability, the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay was carried out
as described previously (8). Briefly, cells were cultured in iso-
tonic or hyperosmotic condition (120mMNaCl) for 24 hwith or
without 1 h pretreatment with celecoxib (40 M) or caspase
inhibitors. After treatments, MTT diluted in PBS was added
(0.5 mg/ml) and incubated for 3 h at 37 °C. Precipitated form-
azan crystals were solubilized in DMSO, and the absorbance
was measured at 570 nm using Infinite 200 Pro microplate
reader (TECAN).
Lentiviral particle production and viral transduction
HEK293T cells were plated in 10-cm plates (5  106 cells/
plate) in DMEM with 10% heat-inactivated FBS 1 day before
transfection. Cells were transfected with 9 g of sh-Ctr or sh-
TonEBP plasmids along with 6 g psPAX2 and 3 g pMD2.G
using Lipofectamine 2000 (Invitrogen). After 6 h, transfection
media were replaced with fresh DMEMwith 10% FBS. Lentivi-
ral media were harvested at 48 to 60 h post transfection, and
virus was precipitated using 7% PEG 6000 solution. NP cells
were transduced with fresh media containing viral particles
along with 8 g/ml Polybrene. Cells were harvested for protein
extraction 4–5 days after transduction to ensure maximum
knockdown efficiency.
Ex vivo disc organ culture
TonEBP/ and haploinsufficient TonEBP/ mice on
C57BL/6 background were socially housed under barrier con-
ditions using aseptic techniques. Mice were provided with Lab
Diet 5010 Laboratory Autoclavable Rodent Diet ad libitum.
Bothmale and femalemice at 4months were sacrificed accord-
ing to the guidelines by the Thomas JeffersonUniversity’s Insti-
tutional Animal Care and Use Committee. Whole spines were
dissected frommice en bloc andmuscle, tendon, and ligaments
were carefully removed. Individualmotion segments, including
vertebral bone and the intervertebral disc were isolated and
allowed to equilibrate overnight in DMEM with 10% FBS. For
each experimental group, lumbar and caudal motion segments
from a single mouse were pooled together. The next day, fresh
media with or without 110 mM NaCl were added for 8 h. After
treatment, vertebrae and bony endplates were removed from
the intervertebral disc using a dissecting microscope (Zeiss
Stemi 305), and discs were snap frozen in liquid nitrogen and
pulverized using a BioSpec BioPulverizer before RNA isolation.
Statistical analysis
All measurements were performed in at least three indepen-
dent experiments. No data were excluded. Data are presented
as the mean  S.D. Differences between groups were assessed
by Student’s t test and analysis of variance (ANOVA) with
appropriate post-hoc analysis using Prism 6 (GraphPad Soft-
ware). p 0.05 was considered statistically significant.
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